FDA
-
-
-
-
-
-
-
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study
-
-
-
-
-
-
-
Lyra Therapeutics (LYRA) Appoints Richard Nieman as Chief Medical Officer
-
-
-
-
-
-
-
Lyra Therapeutics (LYRA) Reports Positive Data from LANTERN Phase 2 Study of LYR-210
-
-
-
-
-
-
-
Lyra Therapeutics (LYRA) Reports Q4; Provides Corporate Update
-
-
-
-
-
-
-
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients
-
251,775 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All